Camlin Fine Sciences Share Price Today (CAMLINFINE)
TODAY IN ONE LINE
CAMLINFINE jumped 3.2% on light volume, outperforming Nifty's -0.4% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹2,370.47 Cr., it trades at a P/E of 87.01. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Camlin Fine Sciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
Red Flags
- ●Sales ContractionQuarterly sales dropped 1.6% YoY
- ●Poor Capital ReturnsLow ROE of 1.3%
- ●Expensive ValuationTrading at a high P/E ratio of 91.5x
- ●Rising Receivables vs SalesReceivables grew 15.5% outpacing sales growth of 14.6%
- ●Promoter Pledging DetectedPledge activity recorded on 17-Mar-2026 16:44
Latest Camlin Fine Sciences News
What changed recently?
Recent events, corporate actions, and announcements.
Camlin Fine Sciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Camlin Fine Sciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
Camlin Fine Sciences Limited trades at a P/E of 87.01× and P/B of 2.31×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Camlin Fine Sciences Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Camlin Fine Sciences Limited — derived from the live tape, not yesterday's close.
Camlin Fine Sciences Limited last traded at ₹124.47 with an intraday range of ₹118.75–₹125 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹124.47| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 139.23 | +14.76 | +11.86% |
| R3 | 132.98 | +8.51 | +6.84% |
| R2 | 128.99 | +4.52 | +3.63% |
| R1 | 126.73 | +2.26 | +1.82% |
| PIVOT | 122.74 | -1.73 | -1.39% |
| CURRENT | 124.47 | — | — |
| S1 | 120.48 | -3.99 | -3.21% |
| S2 | 116.49 | -7.98 | -6.41% |
| S3 | 114.23 | -10.24 | -8.23% |
| S4 | 107.98 | -16.49 | -13.25% |
CAMLINFINE is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹118.75–₹120.28
Trading Above opening range, showing Bullishness
Camlin Fine Sciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Camlin Fine Sciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Camlin Fine Sciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,370.47 Cr. and reported EPS of ₹-1.55.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,667 | 1,723 ▲ 3.4% |
| Sales Growth YoY %Derived | 3.31% | 3.41% |
| Other Income | 14 | 29 ▲ 99.2% |
| Total Income | 1,681 | 1,752 ▲ 4.2% |
| 849 | 922 ▲ 8.6% | |
| Gross ProfitDerived | 817 | 801 ▼ 2.0% |
| Gross Margin %Derived | 49.04% | 46.47% |
| 609 | 694 ▲ 13.9% | |
| EBITDA (Operating Profit)Derived | 208 | 107 ▼ 48.6% |
| OPM %Derived | 12.49% | 6.20% |
| 154 | 118 ▼ 23.1% | |
| Profit Before Tax (PBT) | 49 | -34 ▼ 168.6% |
| 0 | -0 ▼ 784.4% | |
| Effective Tax %Derived | 0.14% | 1.35% |
| Profit/Loss from Discontinued Ops | -208 | 55 ▲ 126.5% |
| Total Profit for Period | -158 | 24 ▲ 114.9% |
| Less: Non-controlling Interests | -19 | -4 ▲ 78.6% |
| Net Profit (Owner's PAT)Derived | -139 | 28 ▲ 119.9% |
| Net Profit Margin %Derived | -8.34% | 1.60% |
| PAT Growth YoY %Derived | -49.91% | 119.87% |
| Earnings Per Share (EPS ₹) | -7.40 | 1.44 ▲ 119.5% |
| Diluted Shares Outstanding (Cr) | 19 | 19 ▲ 2.2% |
| Share of Profit from Associates/JVs | 0 | 2 ▲ 275.9% |
| Other Comprehensive Income (Net of Tax) | -12 | 3 ▲ 128.1% |
| Total Expenses (incl. D&A & Interest) | 1,632 | 1,786 ▲ 9.4% |
| Material Cost % of RevenueDerived | 47.18% | 47.77% |
| Employee Cost % of RevenueDerived | 11.54% | 14.15% |
| Other Cost % of RevenueDerived | 25.01% | 26.12% |
| Interest Coverage (x)Derived | 1.44x | 0.49x |
| Period | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 723 | 723 ▲ 0.0% | 892 ▲ 23.4% | 1,049 ▲ 17.6% | 1,187 ▲ 13.1% | 1,412 ▲ 19.0% | 1,682 ▲ 19.1% | 1,613 ▼ 4.1% | 1,667 ▲ 3.3% | 1,723 ▲ 3.4% | |
| Sales Growth YoY %Derived | — | — | 23.44% | 17.60% | 13.15% | 18.95% | 19.08% | -4.07% | 3.31% | 3.41% | |
| Other Income | 12 | 12 ▲ 0.0% | 14 ▲ 19.3% | 3 ▼ 75.1% | 5 ▲ 45.4% | 33 ▲ 562.8% | 6 ▼ 82.4% | 16 ▲ 168.2% | 14 ▼ 7.1% | 29 ▲ 99.2% | |
| Total Income | 734 | 734 ▲ 0.0% | 906 ▲ 23.4% | 1,053 ▲ 16.2% | 1,192 ▲ 13.3% | 1,445 ▲ 21.2% | 1,687 ▲ 16.8% | 1,629 ▼ 3.5% | 1,681 ▲ 3.2% | 1,752 ▲ 4.2% | |
422 | 422 ▲ 0.0% | 475 ▲ 12.4% | 534 ▲ 12.4% | 583 ▲ 9.3% | 759 ▲ 30.2% | 813 ▲ 7.1% | 914 ▲ 12.3% | 849 ▼ 7.0% | 922 ▲ 8.6% | ||
| Gross ProfitDerived | 300 | 300 ▲ 0.0% | 417 ▲ 39.0% | 515 ▲ 23.5% | 604 ▲ 17.1% | 653 ▲ 8.1% | 868 ▲ 33.1% | 699 ▼ 19.5% | 817 ▲ 16.8% | 801 ▼ 2.0% | |
| Gross Margin %Derived | 41.55% | 41.55% | 46.78% | 49.12% | 50.85% | 46.21% | 51.64% | 43.36% | 49.04% | 46.47% | |
288 | 288 ▲ 0.0% | 349 ▲ 21.2% | 385 ▲ 10.3% | 422 ▲ 9.6% | 500 ▲ 18.5% | 663 ▲ 32.7% | 626 ▼ 5.7% | 609 ▼ 2.6% | 694 ▲ 13.9% | ||
| EBITDA (Operating Profit)Derived | 13 | 13 ▲ 0.0% | 69 ▲ 447.0% | 131 ▲ 90.4% | 182 ▲ 39.2% | 153 ▼ 16.0% | 205 ▲ 34.3% | 74 ▼ 64.0% | 208 ▲ 181.6% | 107 ▼ 48.6% | |
| OPM %Derived | 1.74% | 1.74% | 7.70% | 12.46% | 15.33% | 10.82% | 12.21% | 4.58% | 12.49% | 6.20% | |
55 | 55 ▲ 0.0% | 66 ▲ 19.4% | 76 ▲ 15.6% | 82 ▲ 7.8% | 92 ▲ 12.1% | 111 ▲ 21.4% | 89 ▼ 20.0% | 154 ▲ 72.7% | 118 ▼ 23.1% | ||
| Profit Before Tax (PBT) | -31 | -31 ▲ 0.0% | 17 ▲ 154.2% | 58 ▲ 247.4% | 105 ▲ 80.6% | 94 ▼ 10.5% | 80 ▼ 14.6% | -99 ▼ 223.5% | 49 ▲ 149.4% | -34 ▼ 168.6% | |
-7 | -7 ▲ 0.0% | 14 ▲ 302.6% | 28 ▲ 107.3% | 40 ▲ 40.1% | 34 ▼ 15.4% | 41 ▲ 20.7% | 6 ▼ 86.1% | 0 ▼ 98.8% | -0 ▼ 784.4% | ||
| Effective Tax %Derived | 21.86% | 21.86% | 81.71% | 48.74% | 37.81% | 35.71% | 50.47% | -5.67% | 0.14% | 1.35% | |
| Profit/Loss from Discontinued Ops | — | — | — | — | — | — | — | — | -208 | 55 ▲ 126.5% | |
| Total Profit for Period | -24 | -24 ▲ 0.0% | 3 ▲ 112.5% | 30 ▲ 892.4% | 65 ▲ 119.1% | 60 ▼ 7.6% | 40 ▼ 34.1% | -105 ▼ 363.4% | -158 ▼ 50.8% | 24 ▲ 114.9% | |
| Less: Non-controlling Interests | 6 | 6 ▲ 0.0% | -1 ▼ 117.2% | -0 ▲ 49.9% | 14 ▲ 3050.9% | -0 ▼ 102.1% | -12 ▼ 3919.6% | -12 ▲ 1.4% | -19 ▼ 57.4% | -4 ▲ 78.6% | |
| Net Profit (Owner's PAT)Derived | -30 | -30 ▲ 0.0% | 4 ▲ 113.4% | 30 ▲ 661.9% | 51 ▲ 68.1% | 61 ▲ 19.1% | 52 ▼ 14.1% | -93 ▼ 278.0% | -139 ▼ 49.9% | 28 ▲ 119.9% | |
| Net Profit Margin %Derived | -4.10% | -4.10% | 0.45% | 2.89% | 4.29% | 4.30% | 3.10% | -5.75% | -8.34% | 1.60% | |
| PAT Growth YoY %Derived | — | — | 113.42% | 661.93% | 68.09% | 19.06% | -14.13% | -278.01% | -49.91% | 119.87% | |
| Earnings Per Share (EPS ₹) | -2.55 | -2.18 ▲ 14.5% | 0.29 ▲ 113.3% | 2.23 ▲ 669.0% | 3.56 ▲ 59.6% | 3.45 ▼ 3.1% | 2.96 ▼ 14.2% | -4.94 ▼ 266.9% | -7.40 ▼ 49.8% | 1.44 ▲ 119.5% | |
| Diluted Shares Outstanding (Cr) | 12 | 14 ▲ 16.9% | 14 ▲ 0.0% | 14 ▲ 0.0% | 14 ▲ 5.1% | 18 ▲ 23.1% | 18 ▲ 0.1% | 19 ▲ 6.6% | 19 ▲ 0.0% | 19 ▲ 2.2% | |
| Share of Profit from Associates/JVs | 0 | 0 ▲ 0.0% | -0 ▼ 134.3% | -0 ▲ 98.5% | — ▲ 100.0% | -0 | — ▲ 100.0% | — | 0 | 2 ▲ 275.9% | |
| Other Comprehensive Income (Net of Tax) | 12 | 12 ▲ 0.0% | 1 ▼ 95.7% | 1 ▲ 144.1% | 114 ▲ 8618.1% | -8 ▼ 106.8% | 20 ▲ 360.5% | 18 ▼ 11.2% | -12 ▼ 168.1% | 3 ▲ 128.1% | |
| Total Expenses (incl. D&A & Interest) | 765 | 765 ▲ 0.0% | 889 ▲ 16.2% | 994 ▲ 11.8% | 1,087 ▲ 9.3% | 1,351 ▲ 24.3% | 1,607 ▲ 18.9% | 1,728 ▲ 7.5% | 1,632 ▼ 5.6% | 1,786 ▲ 9.4% | |
| Material Cost % of RevenueDerived | 53.20% | 53.20% | 52.60% | 47.63% | 41.11% | 51.53% | 50.88% | 46.29% | 47.18% | 47.77% | |
| Employee Cost % of RevenueDerived | 10.08% | 10.08% | 9.85% | 9.50% | 10.14% | 10.27% | 9.67% | 11.08% | 11.54% | 14.15% | |
| Other Cost % of RevenueDerived | 29.73% | 29.73% | 29.23% | 27.16% | 25.38% | 25.12% | 29.76% | 27.70% | 25.01% | 26.12% | |
| Interest Coverage (x)Derived | -0.50x | -0.50x | 1.08x | 2.27x | 3.67x | 2.71x | 2.44x | -0.08x | 1.44x | 0.49x |
Camlin Fine Sciences segment analysis : revenue and profit mix.
Disclosed business segments at Camlin Fine Sciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Camlin Fine Sciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Camlin Fine Sciences Limited.
Our AI distills the core fundamental drivers supporting Camlin Fine Sciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Camlin Fine Sciences Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter holding 48.03% demonstrates strong ownership commitment and shareholder alignment
Operating cash flow positive ₹67.14 Cr supports liquidity and operational viability
Latest quarterly sales grew 11.20% YoY, signaling revenue recovery momentum despite contraction
Established 1931 heritage with diversified specialty chemicals portfolio serving global markets
Debt-to-equity ratio 0.51x moderate, manageable leverage for industrial company
Key Risks.
TTM revenue declined 2.90% YoY, indicating persistent top-line contraction pressure
Latest quarterly EPS negative at ₹-1.59, reflecting current unprofitable operations
ROE negative at -3.36%, destroying shareholder value and capital efficiency
Operating margin 2.09% TTM far below specialty chemicals peer average 10-27%
Negative pretax margin -2.12% TTM threatens operational sustainability and growth
Flip Conditions.
Valuation risk. a P/E above 113 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.19. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Camlin Fine Sciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Camlin Fine Sciences Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Camlin Fine Sciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Camlin Fine Sciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Camlin Fine Sciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Camlin Fine Sciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Camlin Fine Sciences Limited stood at 48.5% of traded volume, against a 20-day average of 46.5%.
Camlin Fine Sciences announcements: results, concalls, ratings, M&A.
Filings Camlin Fine Sciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Camlin Fine Sciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 158 documents below.
General Updates
Camlin Fine Sciences Limited has informed the Exchange about letters sent to Shareholders.
Shareholders meeting
Camlin Fine Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 11, 2026
Copy of Newspaper Publication
Camlin Fine Sciences Limited has informed the Exchange about Copy of Newspaper Publication pursuant to 33rd Annual General Meeting of the Company.
General Updates
Camlin Fine Sciences Limited has informed the Exchange about Press Release issued by the Company.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Camlin Fine Sciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Investor decks & rating reports.
Camlin Fine Sciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Camlin Fine Sciences has declared, sequenced by announce and record date.
Camlin Fine Sciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Camlin Fine Sciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Camlin Fine Sciences as reported to SEBI — buying and selling signals from the people who know the business best.
Camlin Fine Sciences insider activity below tracks 8 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Ashish Subhash Dandekar | Insider | 17 Apr 2026 | buy | +32.96 L | ₹35.07 Cr. | ₹106.40 |
| Ashish Subhash Dandekar | Insider | 07 Apr 2026 | buy | +12.50 L | ₹12.98 Cr. | ₹103.86 |
| Ashish Subhash Dandekar | Insider | 30 Mar 2026 | buy | +6.50 L | ₹6.3 Cr. | ₹96.93 |
| Ashish Subhash Dandekar | Insider | 25 Mar 2026 | buy | +7.00 L | ₹7.88 Cr. | ₹112.51 |
| Ashish Subhash Dandekar | Insider | 11 Mar 2026 | buy | +34.75 L | ₹49.56 Cr. | ₹142.63 |
| Ashish Subhash Dandekar | Insider | 11 Mar 2026 | buy | +34.75 L | ₹49.56 Cr. | ₹142.63 |
| Ashish Subhash Dandekar | Insider | 11 Mar 2026 | buy | +34.75 L | ₹49.56 Cr. | ₹142.63 |
| Ashish Subhash Dandekar | Insider | 11 Mar 2026 | buy | +34.75 L | ₹49.56 Cr. | ₹142.63 |
About Camlin Fine Sciences Limited: business, sector, key facts.
What Camlin Fine Sciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Camlin Fine Sciences Limited operates in the Specialty Chemicals industry under the Chemicals sector, listed as NSE: CAMLINFINE, BSE: 532834.
Camlin Fine Sciences Limited (CFSL) is a prominent player in the specialty chemicals industry, operating both domestically within India and on a global scale. The company's core business revolves around the research, development, manufacturing, and marketing of a diverse range of specialty chemicals, ingredients, and additive blends. Their offerings cater to a wide array of sectors, highlighting the versatility and broad applicability of their product portfolio.
A significant portion of CFSL's business focuses on providing shelf-life enhancement solutions for various industries. This includes a comprehensive selection of antioxidants (like Butylated Hydroxy Toluene and Ascorbyl palmitate), emulsifiers, mold inhibitors, antibacterial agents, and other preservatives. They also offer a compelling line of plant-based antioxidants, such as mixed tocopherols, green tea extract, and rosemary extract, marketed under their Xtendra and NaSure brands. These solutions are particularly valuable in extending the usability and quality of products across multiple sectors.
Beyond shelf-life solutions, CFSL also manufactures and distributes aroma ingredients, such as vanillin and ethyl vanillin, which are critical components in the fragrance and flavor industries. Furthermore, they delve into the health and wellness sector with dedicated products and offer performance chemicals like hydroquinone and catechol, demonstrating a commitment to diverse market segments and applications.
The company's clientele spans a broad spectrum of industries, including food and beverage, pet food, animal nutrition, rendering, health and wellbeing, general chemicals, biofuel, and aroma technical applications. This diversified customer base underscores the widespread demand for CFSL's high-quality specialty chemicals and contributes to the company's robust market position. Established in 1931 and headquartered in Mumbai, India, Camlin Fine Sciences Limited has a long history of innovation and adaptation within the ever-evolving chemical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarti Industries (AARTIIND) Share PricePeer
- Aarti Surfactants (AARTISURF) Share PricePeer
- Archean Chemical Industries (ACI) Share PricePeer
- Aether Industries (AETHER) Share PricePeer
- Alkali Metals (ALKALI) Share PricePeer
- Top Gainers TodayScreener
- Other overvalued NSE stocksScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Camlin Fine Sciences Limited (CAMLINFINE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Camlin Fine Sciences Limited (CAMLINFINE)?
The current share price of Camlin Fine Sciences Limited (CAMLINFINE) is ₹124.47. Today, the stock has gained by ₹3.86 (3.20%), trading in a range of ₹118.75 to ₹125. The stock opened at ₹119.7 with a trading volume of 4,70,517 shares.
02Is Camlin Fine Sciences Limited stock a good investment for long-term?
Camlin Fine Sciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,370.47 crores, P/E ratio of 87.01, ROE of 1.26%, and ROCE of 4.05%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Camlin Fine Sciences Limited stock?
The 52-week high price of Camlin Fine Sciences Limited (CAMLINFINE) is ₹235, while the 52-week low is ₹96.21. Currently trading at ₹124.47, the stock is 20.4% away from its 52-week low and 47.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Camlin Fine Sciences Limited stock at the current price?
Whether to buy Camlin Fine Sciences Limited stock at ₹124.47 depends on multiple factors. The stock is currently trading with a P/E ratio of 87.01 and P/B ratio of 2.31. Today's performance shows a gain of 3.20%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Camlin Fine Sciences Limited and when is the next dividend?
Camlin Fine Sciences Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹124.47, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Camlin Fine Sciences Limited?
Camlin Fine Sciences Limited's key financial metrics include: P/E Ratio: 87.01, P/B Ratio: 2.31, ROE: 1.26%, ROCE: 4.05%, Dividend Yield: 0.00%, EPS: ₹-1.55, Book Value: ₹54.17, and Debt-to-Equity: 0.69. The company's market cap stands at ₹2,370.47 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Camlin Fine Sciences Limited stock performing today in the market?
Camlin Fine Sciences Limited stock opened at ₹119.7 and is currently trading at ₹124.47, showing a gain of ₹3.86 (3.20%). The intraday high is ₹125 and low is ₹118.75. The trading volume stands at 4,70,517 shares, indicating moderate market participation today.
08What is the P/E ratio of Camlin Fine Sciences Limited and what does it indicate?
Camlin Fine Sciences Limited has a Price-to-Earnings (P/E) ratio of 87.01, which means investors are willing to pay ₹87.01 for every ₹1 of earnings. With an EPS of ₹-1.55, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Camlin Fine Sciences Limited (CAMLINFINE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.